Better diabetic retinopathy outcomes seen with monthly ranibizumab

09/6/2013 | Medscape (free registration)

Data on diabetic retinopathy patients showed those who received monthly ranibizumab treatment were more likely than those who received sham injections to attain improvements in vision and disease severity at three years. Researchers also found patients in the ranibizumab arm were three times less likely to develop proliferative diabetic retinopathy than those in the control group. The findings were presented at the American Society of Retina Specialists meeting.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC